Constrained Optimization for the Selection of Influenza Vaccines to Maximize the Population Benefit: A Demonstration Project
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1179-1896
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Constrained Optimization for the Selection of Influenza Vaccines to Maximize the Population Benefit: A Demonstration Project ; day:22 ; month:11 ; year:2019 ; pages:1-13
Applied health economics and health policy ; (22.11.2019), 1-13
- Urheber
-
Standaert, Baudouin
Van Vlaenderen, Ilse
Van Bellinghen, Laure-Anne
Talbird, Sandra
Hicks, Katherine
Carrico, Justin
Buck, Philip O.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s40258-019-00534-y
- URN
-
urn:nbn:de:101:1-2020032607465752394782
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:59 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Standaert, Baudouin
- Van Vlaenderen, Ilse
- Van Bellinghen, Laure-Anne
- Talbird, Sandra
- Hicks, Katherine
- Carrico, Justin
- Buck, Philip O.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Vaccines for pandemic influenza
Influenza vaccines for the future
Better influenza vaccines: an industry perspective
Selecting the neoadjuvant treatment by molecular subtype: how to maximize the benefit?
Constrained evolution drives limited influenza diversity
Cost Effectiveness of Quadrivalent Influenza Vaccines Compared with Trivalent Influenza Vaccines in Young Children and Older Adults in Korea
Individualizing therapy – in search of approaches to maximize the benefit of drug treatment (II)
Benefit-Risk Assessment of Vaccines. Part II: Proposal Towards Consolidated Standards of Reporting Quantitative Benefit-Risk Models Applied to Vaccines (BRIVAC)
Debate on the compositions of influenza B in northern hemisphere seasonal influenza vaccines
Factors affecting the immunogenicity of influenza vaccines in human
Benefit–Risk Assessment of Vaccines. Part I: A Systematic Review to Identify and Describe Studies About Quantitative Benefit–Risk Models Applied to Vaccines
Titrating droxidopa to maximize symptomatic benefit in a patient with Parkinson disease and neurogenic orthostatic hypotension
Vaccines for pandemic influenza
Influenza vaccines for the future
Better influenza vaccines: an industry perspective
Selecting the neoadjuvant treatment by molecular subtype: how to maximize the benefit?
Constrained evolution drives limited influenza diversity
Cost Effectiveness of Quadrivalent Influenza Vaccines Compared with Trivalent Influenza Vaccines in Young Children and Older Adults in Korea
Individualizing therapy – in search of approaches to maximize the benefit of drug treatment (II)
Benefit-Risk Assessment of Vaccines. Part II: Proposal Towards Consolidated Standards of Reporting Quantitative Benefit-Risk Models Applied to Vaccines (BRIVAC)
Debate on the compositions of influenza B in northern hemisphere seasonal influenza vaccines
Factors affecting the immunogenicity of influenza vaccines in human
Benefit–Risk Assessment of Vaccines. Part I: A Systematic Review to Identify and Describe Studies About Quantitative Benefit–Risk Models Applied to Vaccines
Titrating droxidopa to maximize symptomatic benefit in a patient with Parkinson disease and neurogenic orthostatic hypotension
Vaccines for pandemic influenza
Influenza vaccines for the future
Better influenza vaccines: an industry perspective
Selecting the neoadjuvant treatment by molecular subtype: how to maximize the benefit?
Constrained evolution drives limited influenza diversity
Cost Effectiveness of Quadrivalent Influenza Vaccines Compared with Trivalent Influenza Vaccines in Young Children and Older Adults in Korea
Individualizing therapy – in search of approaches to maximize the benefit of drug treatment (II)
Benefit-Risk Assessment of Vaccines. Part II: Proposal Towards Consolidated Standards of Reporting Quantitative Benefit-Risk Models Applied to Vaccines (BRIVAC)
Debate on the compositions of influenza B in northern hemisphere seasonal influenza vaccines
Factors affecting the immunogenicity of influenza vaccines in human
Benefit–Risk Assessment of Vaccines. Part I: A Systematic Review to Identify and Describe Studies About Quantitative Benefit–Risk Models Applied to Vaccines